Catch up with the latest episodes of our #PodcastSeries as Shaji Kumar is joined by Taxiarchis Kourelis and Vaishali Sanchorawala to discuss practical steps in recognizing #ALAmyloidosis early, plus emerging modalities that may impact standard care

ow.ly/Yt1I50Yrrkr

You don't have to face #myeloma or #ALamyloidosis alone.
MPE's 52 member organisations across 33 countries offer local expertise, peer support and advocacy. Find information, community and help navigating your healthcare system: https://f.mtr.cool/qnokbybxhw

#WellnessWednesday

AL Amyloidosis vs ATTR-CM: Clinical Insights and Diagnostic Challenges This article explores key differences and diagnostic challenges between light-chain amyloidosis and ATTR-CM.

Accurate differentiation between light-chain (AL) amyloidosis and #ATTRCM is critical for effective patient management, as misclassification can delay life-saving therapies for #ALAmyloidosis or result in unnecessary interventions for ATTR-CM.

Learn more: https://bit.ly/4q8BrAH

S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.

Elranatamab May Be Effective for Light Chain Amyloidosis Researchers determined elranatamab may be an effective treatment for patients with advanced immunoglobulin light-chain amyloidosis and further study is warranted.

Elranatamab treatment of patients with advanced immunoglobulin light-chain #amyloidosis resulted in a 100% overall response rate. Published in @bloodjournals.hematology.org.

https://bit.ly/4s4uSR7

#ALAmyloidosis

What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates.
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213

The new AL International Staging System (AL-ISS) is here, defining Stage IIIC as an ultra-poor risk. Simultaneous publication at #ASH25! This is a major step for diagnosis and patient care.

👉 Read the full abstract: brnw.ch/21wYb73
#ALamyloidosis #Hematology

Sharing our trial in progress, IMPACT AL, testing teclistamab combined with daratumumab in newly diagnosed #alamyloidosis at #ASH25 meetin. Excited to work with Drs Chakraborty, Lentzsch, and Sanchorawala, with funding from J&J and SU2C.

Enrolling: SWOG S2213 in newly diagnosed #ALamyloidosis. Daratumumab + VCD induction, then randomization to autologous stem cell transplant or Dara-VCD consolidation. Patients on both arms get dara maintenance.
Co-PI: @surbhisidanamd.bsky.social Stanford Medicine
SWOG.org/clinical-trials/S2213

MPE is attending the @ash.hematology.org annual congress in Orlando, Florida. Over the next few days, we will follow the key updates in #myeloma and #ALamyloidosis and speak with leading experts to understand what they mean for patients.
#ASH25

FDA Grants Traditional Approval to Darzalex Faspro for AL Amyloidosis The FDA has granted traditional approval to Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adults with newly diagnosed light chain amyloidosis.

The @fda.gov has granted traditional approval to Darzalex Faspro® in combination with VCd for the treatment of adults with newly diagnosed #ALAmyloidosis. From @medicalprofref.bsky.social.

https://bit.ly/44hz4Tm

Study S2213 is for people with newly diagnosed #ALAmyloidosis. It compares a combination of immunotherapy and chemo drugs (called Dara-VCD) to stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. Ask about S2213. #raredisease #mmsm

Localization of the amyloidogenic LC in MNH::mCherry worms. (A) Representative confocal image of MNH::mCherry worms on the first day of adulthood, showing a positive mCherry signal in the body-wall muscle (white arrows) and in coelomocytes (asterisks), demonstrating uptake of the secreted LC. A positive signal was also detected in the anterior region of the worm, including the pharynx (white dashed line box). (B) A picture representing LC-tagged synthesized in body-wall muscle cells by MNH::mCherry nematodes, their secretion pathway and coelomocyte uptake.

Margherita Romeo & co generate the first transgenic C. elegans strain as a model of immunoglobulin light chain amyloidosis to investigate the mechanisms underlying the cardiac-specific toxicity occurring in the disease.
doi.org/10.1242/dmm....

#ALAmyloidosis

Management recommendations for #kidneytransplantation in patients with plasma cell dyscrasia

doi.org/10.1016/j.kint.2025.07.011

#NephSky #MedSky #kidneytransplant #multiplemyeloma #ALamyloidosis #monoclonalgammopathy #meetingreport

Don’t go breaking your heart (Treatment Days 136-139) Monday An absolute ripper of a rehab day. Which of course resulted in me pushing myself a bit too hard. I seemed to have also been able to time my fondue explosions. Although I think it might also …

In which i learn my heart is failing…but slowly

#amyloidosis
#ALAmyloidosis
#disability

5yearsplus.wordpress.com/2025/05/10/d...

Have you tuned into ‘Navigating AL Amyloidosis’ yet? Don’t miss our expert podcast series, hosted by Dr Shaji Kumar, covering key topics from avoiding diagnostic delay to the patient’s perspective #MedSky #MedicalEducation #ALAmyloidosis

ow.ly/8Ecl50VJNIA

#ALamyloidosis is a rare condition characterized by the deposition of immunoglobulin light chains in organs. The ANDROMEDA study assessed the addition of DARA to the standard VCd regimen. Read the results: journals.lww.com/oncology-tim...

My #ASH24 highlights from yesterday were the talks that emphasised the importance of increasing awareness of #MGUS, monoclonal gammopathies of clinical significance like #MGRS and #MGNS, and #ALAmyloidosis so patients can be diagnosed earlier.

Light chain dimers in native conditions are not all the same, check what we found! #alAmyloidosis